NCT04669951

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Michael Patrick Achiam · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Detailed description

* Sections of the tumor tissue will be HE stained. * Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. * Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern. * A semiqualitative scale corresponding to the level of uPAR expression will be made. * Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern. * An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.

Conditions

• Esophagus Cancer, Adenocarcinoma

Interventions

Type	Name	Description
OTHER	uPAR immunohistochemistry	Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression

Timeline

• Start date: 2019-11-18
• Primary completion: 2020-11-30
• Completion: 2020-11-30
• First posted: 2020-12-17
• Last updated: 2021-06-03

Locations

1 site across 1 country: Denmark